Novo Nordisk price target lowered to DKK 900 from DKK 1,050 at Barclays

Barclays lowered the firm’s price target on Novo Nordisk (NVO) to DKK 900 from DKK 1,050 and keeps an Overweight rating on the shares. The firm says that while CagriSema is likely to be a “far superior drug” and will allow Novo to life cycle manage its “way past” the semaglutide loss of exclusivity, it needs to see more detailed data to understand how it compares to tirzepatide.